Published December 29, 2021
| Version v1
Journal article
Open
New <i>ABO</i> intron 1 variant alleles
Authors/Creators
- 1. Laboratory Manager, Thermo Fisher Scientific , Austin , TX USA
- 2. Executive at American Red Cross Biomedical Services , Philadelphia, PA , USA
- 3. Retired from Fondazione IRCCS Ca'Granda–Ospedale Maggiore Policlinico , Milan , Italy
- 4. Cinzia Paccapelo, SDc Biology, Senior Assistant in Immunohematology, Fondazione IRCCS Ca'Granda–Ospedale Maggiore Policlinico , Milan , Italy
- 5. Head, Department of Hematology and Blood Bank Narodna Transfuzna Sluzba SR , Bratislava , Slovakia
- 6. Specialist in Transfusion Medicine, Narodna Transfuzna Sluzba SR , Bratislava , Slovakia
- 7. Blood Bank Supervisor, Elmhurst Memorial Hospital , Elmhurst, IL , United Kingdom
- 8. Medical Director of Blood Bank, Elmhurst Memorial Hospital , Elmhurst, IL , United Kingdom
- 9. Assistant Professor of Internal Medicine, University of Utah Health , Salt Lake City , UT
- 10. Medical Director of Transfusion Service, University of Utah Health , Salt Lake City , UT
- 11. Medical Director, Immunoematologia e Centro Trasfusionale , ASST Valle Olona , varese , Italy
- 12. Lab Technician, Immunoematologia e Centro Trasfusionale , ASST Valle Olona , varese , Italy
- 13. Biologist, Laboratory Director, Servizio di Immunoematologia e Medicina Trasfusionale , Ragusa , Italy
- 14. Biologist, Executive Biologist, Servizio di Immunoematologia e Medicina Trasfusionale , Ragusa , Italy
- 15. Immunohematologist, Independent Consultant , Wimberly , TX , USA
- 16. New York Blood Center , 45-01 Vernon Boulevard , Long Island City , NY 11101 USA
Description
Abstract
Unusual and discrepant ABO phenotypes are often due to genetic variants that lead to altered levels or activity of ABO transferases and consequently to altered expression of ABO antigens. This report describes eight genetic alterations found in 15 cases with reduced or undetectable expression of ABO antigens. Forward and reverse ABO grouping was performed by standard gel or tube methods. Adsorption-heat elution and saliva testing for H and A substances followed the AABB technical manual procedures. Genomic DNA extracted from whole blood was PCR-amplified to cover the entire ABO coding sequence, splice junctions, proximal promoter, and intron 1 enhancer. Amplification products were sequenced by next-generation or Sanger dideoxy methods, either directly or after cloning into a bacterial plasmid vector. Eight unreported alleles were found in the 15 cases analyzed. Alleles ABO*A(28+1C) and ABO*A(29–5G) harbor variants that alter the consensus sequence at the intron 1 donor and acceptor splice sites, respectively. The other alleles harbor variants that alter the consensus sequence at transcription factor–binding sites in the intron 1 enhancer: specifically, ABO*A(28+5792T), ABO*A(28+5859A), and ABO*A(28+5860G) at GATA-1 sites; ABO*B(28+5877T) and ABO*B(28+5878G) at a RUNX1 site; and ABO*A(28+5843A) at or near a C/EBP site. Molecular and serologic characterization of ABO alleles can help in their future identification and in the resolution of discrepancies.
Files
fulltext.pdf
Files
(732.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:a9bd6beffd6f26e182043bdde50a31c7
|
732.2 kB | Preview Download |